Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn Wounds

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

61 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main goal of this phase III clinical trial is to show safety and efficacy of Oleogel-S10 in the acceleration of wound healing of grade 2a burn wounds.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSH-12)

NCT01657305

Wounds

COMPLETED PHASE3

Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSG-12)

NCT01807650

Wounds

COMPLETED PHASE3

Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Moist Wound Healing Dressing Alone in Accelerating the Epithelialization of Split Thickness Skin Graft Donor Sites

NCT01294254

Accelerating the Epithelialization of Split Thickness Skin Graft

COMPLETED PHASE2

Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10)

NCT01294241

Inherited Epidermolysis Bullosa

COMPLETED PHASE2

Efficacy Of Autologous Epidermal Cell Suspension And Silver Sulfadiazine Ointment In Burn

NCT03162367

Burn

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Oleogel-S10 has shown efficacy and was well tolerated in previous clinical trials in patients with skin lesions. Especially the results in the split-thickness skin graft donor site, which is regarded as an excellent model for any kind of superficial wounds in human skin, suggest that Oleogel-S10 should be efficacious and safe in treatment of grade 2a burns.

The present Phase III clinical trial in grade 2a burns is initiated in order to measure the wound healing progress applying objective methods, i.e., the time to healing and the grade of epithelialization of the wound.

In this study, grade 2a burn wounds are separated into two halves: Following wound cleaning and disinfection, wounds are separated into two wound halves. Randomly assigned, one wound half receives Oleogel-S10 ointment, the other wound half standard of care treatment.

Wound healing progress is documented by photos which are assessed by expert reviewers blinded to the treatment of the wound halves.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Burns

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oleogel-S10 ointment

Intra-individual comparison. Oleogel-S10 ointment is administered to one randomly assigned wound half.

Group Type EXPERIMENTAL

Oleogel-S10 ointment

Intervention Type DRUG

Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing

Octenilin® wound gel

Intervention Type DEVICE

Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing

Octenilin® wound gel

Intraindividual comparison: The other wound half receives disinfectant Octenilin® wound gel.

Group Type OTHER

Oleogel-S10 ointment

Intervention Type DRUG

Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing

Octenilin® wound gel

Intervention Type DEVICE

Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oleogel-S10 ointment

Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing

Intervention Type DRUG

Octenilin® wound gel

Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Contains Octenidine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients at least 18 years old who have provided written informed consent.
* Presenting with acute grade 2a burn wounds (as graded by an expert surgeon assisted by LDI or a multispectral imaging system) within 48 hours after injury.
* Burn wound caused by fire burn, heat burn or scalding.
* Burn patients with grade 2a burn wounds between 80 cm2 and less than 25% of their TBSA (alternatively, 2 comparable wounds with size more than 40 cm2 each and less than 12.5% of the TBSA each are allowed).
* Patient is able to understand the Informed Consent Form provided and is prepared to comply with all study requirements, including the following: Visiting the trial site for wound dressing changes at least every second day (if patient is not hospitalized) and photo documentation until full wound closure or until the Investigator decides to change medication and/or treatment after day 21 after start of treatment
* Willing to perform all necessary wound dressing changes at the trial site. Also the patient needs to agree to return to site for 3 and 12 months follow-up visits.
* Women of childbearing potential must apply highly effective method of birth control (failure rate less than 1% per year when used consistently and correctly (e.g., implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner))

Exclusion Criteria

* Suffering from chemical burns, or electrical burns or sunburns
* Having already received treatment for their burn with silver sulfadiazine (obscures photographic wound evaluation).
* Positive blood culture after the burn.
* Diseases or conditions that could, in the opinion of the Investigator, interfere with the assessment of safety, tolerance or efficacy.
* A skin disorder that is chronic or currently active and which the Investigator considers will adversely affect the healing of the acute wounds or involves the areas to be examined in this trial.
* A history of clinically significant hypersensitivity to any of the drugs or surgical dressings to be used in this trial.
* Known multiple allergic disorders.
* Taking, or have taken, any investigational drugs within 3 months prior to the screening visit.
* Pregnant or breast feeding women are not allowed to participate in the study.
* Inappropriate to participate in the study, for any reason, in the opinion of the Investigator.
* Mental incapacity or language barriers precluding adequate understanding or co-operation or willingness to follow study procedures.
* Previous participation in this study.
* Employee at the investigational site, relative or spouse of the Investigator

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No